The Role of Tyrosine Kinase Inhibitors in Unresectable Hepatocellular Carcinoma

Richard Finn, MD, and David James Pinato, MD, MRCP, PhD, discuss the role of tyrosine kinase inhibitors in unresectable hepatocellular carcinoma, second-line treatment options, and recent clinical trials.

EP. 1: Examining the Role of Liver Function in HCC

April 16th 2024

Richard Finn, MD, and David James Pinato, MD, MRCP, PhD, discuss driving forces for the development of hepatocellular carcinoma, including different types of viral hepatitis and non-alcoholic steatohepatitis.

EP. 2: HCC Staging: Improving Treatment Strategies

April 16th 2024

The key opinion leaders discuss staging systems they use in clinical practice and their effectiveness in creating treatment algorithms, particularly with respect to Child-Pugh scores.

EP. 3: Locoregional Therapies for Intermediate-Stage HCC

April 23rd 2024

Richard Finn, MD, and David James Pinato, MD, MRCP, PhD, review locoregional therapies for hepatocellular carcinoma, including transarterial chemoembolization (TACE) and radioembolization.

EP. 4: HCC Trials: Insights from the LAUNCH, EMERALD-1, and LEAP-012 Trials

April 23rd 2024

Medical experts discuss the LAUNCH study, EMERALD-1, and LEAP-012 trials, providing updates on the progress and findings that influence the treatment paradigm for hepatocellular carcinoma.

EP. 5: Emerging Therapies in Intermediate-Stage HCC

April 30th 2024

The panelists examine the effectiveness of transarterial chemoembolization (TACE) in treating hepatocellular carcinoma in patients with intermediate-stage disease and discuss the future prospects for these patients.

EP. 6: Updates from IMbrave150, LEAP-002, and HIMALAYA Trials

April 30th 2024

Richard Finn, MD, and David James Pinato, MD, MRCP, PhD, provide an overview of the IMbrave150 study, the LEAP-002 trial, and the HIMALAYA trial, discussing how these trials have changed the treatment landscape for hepatocellular carcinoma.

EP. 7: Comorbidity Considerations for HCC Treatment

May 7th 2024

The panelists discuss factors that may preclude patients from receiving certain therapies, such as cardiovascular comorbidities, which may pose an immediate threat to the patient's life.

EP. 8: The Evolving Landscape of Second-Line Therapies in HCC Management

May 7th 2024

Medical experts discuss the selection of second-line treatments for patients who experience disease progression while on first-line therapy, highlighting the potential for deterioration in performance status and liver function.

EP. 9: Additional Second-Line Treatments for HCC

May 14th 2024

Richard Finn, MD, and David James Pinato, MD, MRCP, PhD, discuss a novel therapy that, although not practice-changing, provides an additional treatment option for patients with hepatocellular carcinoma.

EP. 10: Real-World Evidence on Second-Line Therapy Selection and Outcomes

May 14th 2024

Medical experts discuss how the time to progression, progression patterns, and real-world data influence the provider's choice of treatment for patients with hepatocellular carcinoma.